Research progress of drug eluting balloon in arterial circulatory system
Keji Lu1,2,† Xianglin Ye1,3,† Yaoxuan Chen2,† Peng Wang3 Meiting Gong3 Bing Xuan3 Zhaobing Tang4 Meiling Li3 
Jun Hou5 Ke Peng3* 
Haifeng Pei1,3*
- 1Department of Cardiology, The Affiliated Hospital, Southwest Medical University, Luzhou, China
- 2School of Medical and Life Sciences, Chengdu University of TCM, Chengdu, China
- 3Department of Cardiology, The General Hospital of Western Theater Command, Chengdu, China
- 4Department of Rehabilitation, The General Hospital of Western Theater Command, Chengdu, China
- 5Department of Cardiology, Chengdu Third People's Hospital, Chengdu, China
The arterial circulatory system diseases are common in clinical practice, and their treatment options have been of great interest due to their high morbidity and mortality. Drug-eluting balloons, as a new type of endovascular interventional treatment option, can avoid the long-term implantation of metal stents and is a new type of angioplasty without stents, so drug-eluting balloons have better therapeutic effects in some arterial circulatory diseases and have been initially used in clinical practice. In this review, we first describe the development, process, and mechanism of drug-eluting balloons. Then we summarize the current studies on the application of drug-eluting balloons in coronary artery lesions, in-stent restenosis, and peripheral vascular disease. As well as the technical difficulties and complications in the application of drug-eluting balloons and possible management options, in order to provide ideas and help for future in-depth studies and provide new strategies for the treatment of more arterial system diseases.
Graphical Abstract.
Highlights
1. We describe the development, process, and mechanism of drug-eluting balloons.
2. We summarize the current studies on the application of drug-eluting balloons in coronary artery lesions, in-stent restenosis and peripheral vascular disease.
3. We have summarized numerous clinical trials and demonstrated the safety and effectiveness of drug-eluting balloons in the treatment of diseases including coronary heart disease and lower extremity vascular disease: ① For small vessel, large vessel and bifurcation lesions of coronary artery, their short term efficacy is favorable and safety is high, while their long term efficacy for large vessel lesions of coronary artery is also excellent ② For femoral and popliteal arteries, their performance is also sound ③ For renal blood vessels, children's cardiac vessels and in-stent restenosis, there have been studies or reports proving their treatment feasibility, but a large number of studies are needed to prove their safety and efficacy.
4. By reviewing the progress of drug-eluting balloon research mentioned above, we can provide new ideas for the treatment of more arterial system diseases.
Significance Statement: This review can provide ideas and help for future in-depth studies and provide new strategies for the treatment of more arterial system diseases.
1 Drug eluting balloon overview
New stenosis and restenosis of blood vessels are frequent causes of cardiovascular disease, and angioplasty is one of the main strategies to treat such diseases (1, 2). Drug-eluting balloon (DEB) is a new angioplasty technique which combines balloon angioplasty and drug-eluting technology. It uses a balloon catheter as a delivery medium to deliver drugs that inhibit cell proliferation to the lesion site to achieve vasodilatation and inhibit endothelial cell proliferation at the same time. Because of its good therapeutic effect in preventing intimal proliferation and restenosis, it is increasingly favored by multidisciplinary researchers.
1.1 Traceability of drug eluting balloon
In 1964, Dotter et al. proposed percutaneous transluminal angioplasty to treat inoperable arteriosclerosis stenosis (3). In 1978, Grüntzig et al. developed the expandable balloon technique to propose intraluminal dilation of coronary artery stenosis, which was successfully implemented in clinical practice. Although balloon dilation was limited at that time due to the potential for restenosis with long-term use, it cannot be denied that balloon dilation showed better short-term efficacy (4–6). In the 1980s, Sigwart et al. introduced bare metal stents (BMS) for the treatment of coronary and peripheral artery stenosis, significantly reducing restenosis and occlusion after angioplasty (7). However, the presence of BMS in the vessel lumen for an extended period may lead to stent thrombosis and worsen the condition. It wasn't until the early 21st century that drug-eluting stents (DES) were developed, greatly improving the prevention of stent thrombosis. Rensin et al.'s study, involving 15 Brazilian patients with an average age of 60, demonstrated minimal adverse events following the use of sirolimus drug-eluting stent (8, 9), although in-stent restenosis still remained a concern. In 2003, Scheller et al. conducted an animal model study mixing Paclitaxel and iopromide, revealing effective inhibition of in-stent restenosis (10). They suggested the use of paclitaxel drug balloons as a novel approach for preventing and treating restenosis the following year (11). The 2014 ESC/EACTS guidelines for myocardial revascularization have recommended considering drug-eluting balloons for restenosis (12). Now, the safety and efficacy of drug-eluting balloons have been confirmed and are gradually being utilized in clinical treatment. In recent years, with advancements in technology and research emphasis, drug balloons are no longer limited to restenosis treatment, but also applied to various arterial system diseases. Additionally, new material balloons such as nano drug balloons and micro-needle drug balloons have shown promising therapeutic effects and healing properties in experiments. It is expected that further balloon technologies will be implemented in clinical treatment as technology continues to advance in the future (Figure 1).
Figure 1. The origin of drug balloon. The figure illustrates the creation of percutaneous transluminal angioplasty by Dotter et al. in (3) and used in the treatment of patients with atherosclerosis. In the 1970s, it was found that percutaneous intracoronary balloon angioplasty could be used as a non-surgical dilatation method to improve coronary artery stenosis. In the 1980s, BMS was developed and gradually used to treat coronary artery disease and peripheral artery disease. Until the early 21st century, the combination of drug and stent treatment technology matured and the therapeutic safety of DES was effectively verified, to the point that the effectiveness of DEB for in-stent restenosis has been confirmed and gradually expanded to the treatment of more arterial system diseases.
1.2 Drug eluting balloon production process evolution
The drug-eluting balloon is composed of three main components: the active substance, excipient, and balloon. These components are combined through specific production processes to meet clinical requirements, such as continuous drug delivery at therapeutic doses, long-term maintenance of drug concentration in blood vessel walls, and non-toxicity to the body (13). Various methods exist for attaching drugs to balloons, including spraying, dipping, micropipetting, and using nanoparticles to imprint the drug on the balloon surface. Among these methods, nanoparticle technology stands out due to its ability to encapsulate the drug, firmly attach it to the balloon surface, and achieve controlled release only in the fluid environment at the target site (14, 15). Continuous innovation in coating technology has led to better drug release mechanisms, such as microcapsule coatings, hydrogel coatings, polymer-free coatings, immediate-release coatings, bioadhesive coatings, and multilayer coatings. These advancements enable more uniform and stable wrapping of drugs on the balloon surface, reduce drug loss during delivery, and improve drug delivery to the target site (16, 17). When selecting a drug, it's essential to consider its lipophilicity since the balloon must deliver a large dose of the drug to the target vessel surface within a short time. Ideally, a lipophilic drug is preferred to ensure effective absorption by the vessel wall and tissue retention (18). Currently, paclitaxel is the most commonly used drug for Drug-Eluting Balloons (DEB), but alternative options are being investigated due to potential risks. A comparative trial between paclitaxel-coated balloons and sirolimus-coated balloons showed no significant difference in short-term clinical outcomes, indicating that DEB utilizing Moss family drugs could potentially replace paclitaxel-coated balloons (19). The choice of excipients is equally important as the antiproliferative drugs. During balloon dilation, excipients allow the drug to attach completely to the endothelium and mucus layer. They also ensure stability before gradual controlled release, enabling long-term treatment (20). Commonly used excipients in clinical practice include urea, iopromide, tributyl acetyl citrate, and polyester-based polymers (21). Urea facilitates penetration of the lipophilic portion or drug into the arterial wall, iopromide acts as a hydrophilic spacer, and lipophilic lubricant-type excipients reduce friction between the balloon, polymer layer, and vessel. However, it's important to consider potential vascular inflammation and allergic reactions associated with excipients. In this regard, a research team has developed an excipient-free paclitaxel nano-needle crystal drug balloon, which improves biocompatibility and reduces the risk of distal microvascular embolism by using a unique excipient-free design and a breakthrough of the drug crystal diameter to the nanometer level. In comparison with the current clinical evidence of Symplex drug balloon, it was found that there was no difference in safety and efficacy between the two, which fully proved that the excipient-free paclitaxel nano-needle crystal drug balloon can improve the safety of use and still take into account the excellent efficacy, providing a new development direction for the production of drug balloons. Balloons as material carriers have high requirements for flexibility, mechanical strength, and thickness, the original balloons were made of polyvinyl chloride, but today, balloons are mainly made of thermoplastic polymers, there are also balloons made of cross-linked polyethylene, polypropylene, polyamide, and polyester, depending on the clinical purpose, the balloons can be made in different lengths and diameters (16). Various improvements have been made to the balloon itself to address the problems of short inflation times, inefficient drug delivery, and loss of drug flow. Linear micropatterned drug-eluting balloons improve the efficiency and accuracy of intravascular drug delivery to the target lesion through higher contact area and more effective “drug ramming”, so as to create a fuller contact between the balloon and the luminal side of the vascular tissue (22). Microneedle Drug Eluting Balloon, which combines a 34G micro-needle with a balloon catheter based on a specific array to better distribute the drug in the vessel wall by direct injection, but due to balloon volume limitations, the needle needs to be further improved and reduced (23). At the same time, it has been proposed that an external protective sleeve can be used on the drug balloon to prevent drug loss during administration, and it has been demonstrated by in-vitro simulated dosing tests and animal tests that this method can reduce the loading of paclitaxel on the drug balloon to 30% of the mainstream loading and transfer a large amount of paclitaxel to the vessel wall, and it can be detected throughout the 90-day animal experimental study, this technique will be expected to reduce the possibility of systemic drug toxicity due to the use of paclitaxel drug balloon (24). In recent years, due to the advantages of drug balloons in clinical practice, more and more research has been devoted to the improvement of drug balloons, which improves the accuracy of drug release and reduces the toxicity of drugs to humans.
1.3 Mechanism of action of drug eluting balloon
Before using drug-eluting balloons (DEB), it is necessary to perform pre-dilatation with various types of balloons such as normal balloon, high pressure balloon, cutting balloon, integrating balloon, or sphenoid balloon. This pre-dilatation helps reduce the occurrence of intimal dissection. The ratio of balloon diameter to vessel diameter is generally recommended to be within the range of 0.8:1–1.0:1 (21). Once adequate pre-dilatation is achieved, DEB balloons are employed to dilate the stenosed vessel. During this process, the drug is released from the balloon, allowing it to reach the lesion and penetrate into the vessel wall. This drug release exerts an inhibitory effect on intimal hyperplasia (Figure 2). Some commonly used drug-eluting balloons include DIOR DEB, PACCOCATH DEB, SeQuent DEB, and IN.PACT DEB. These balloons typically utilize Paclitaxel as the drug (25). DIOR DEB has multiple micropores on the balloon surface through which Paclitaxel can be rapidly and efficiently released. PACCOCATH DEB and SeQuent DEB both have Paclitaxel embedded in their coatings, enhancing the solubilization and transfer of the drug. However, the coating substance used in SeQuent DEB rapidly dissolves after balloon expansion. On the other hand, IN.PACT DEB is a relatively new type of balloon that contains the hydrophilic excipient, allantoin, in its coating. This excipient facilitates the release and transfer of paclitaxel to the target lesion (26–30). While Paclitaxel is commonly used as a cell proliferation inhibiting drug in drug-eluting balloons, there are other drugs being explored for their potential in this application. Cells respond differently to different concentrations of Paclitaxel, but all concentrations inhibit mitosis by targeting spindle microtubule dynamics, thereby suppressing cell proliferation. Low concentrations of Paclitaxel delay mitosis but may lead to cell death or aneuploidy. On the other hand, high concentrations of Paclitaxel block mitosis by maintaining the formation of microtubule protein complexes (31, 32). Due to the narrow therapeutic window and challenges in controlling the safe dosage of Paclitaxel, as well as suboptimal inhibition of cell proliferation, there is a growing interest in developing new drugs for drug-eluting balloons. One such drug is rapamycin, which inhibits cell proliferation by targeting the mammalian rapamycin target protein signaling pathway (33). Studies have shown that rapamycin exhibits better inhibition of coronary proliferation compared to Paclitaxel (34), although it may have limited effectiveness in certain lesions. Apart from Paclitaxel and rapamycin, other drugs like sirolimus and everolimus are also being investigated for their ability to stabilize blood vessels and enhance the effect of drug-eluting balloons (35).
Figure 2. Mechanism of drug balloon action. The diagram illustrates the process of drug balloon after entering the vessel, the balloon expands at the lesion, enlarging the lumen of the vessel, and the drug inside the balloon reaches the vessel wall with the excipient through the atherosclerotic material present in the vessel wall and is absorbed by the vessel wall to act.
2 The application of drug eluting balloon in arterial circulatory diseases
Until now, interventional procedures have been the most common treatment option for cardiovascular disease, DEB is one of the latest technologies developed as a new clinical treatment modality for coronary artery lesions and peripheral artery disease. Compared to traditional balloon and trans-stenting techniques, DEB can be used in combination with BMS or alone, offering advantages such as uniform drug delivery to the vessel wall, no metallic foreign body residue, reduced antiplatelet treatment time, and reduced restenosis rates (11, 36–38). At present, there are numerous studies showing that DEB has better results in the treatment of coronary artery disease and peripheral vascular disease. Especially in the treatment of coronary artery disease, DEB has better long-term treatment effect than BMS and DES techniques (39) (Table 1 and Figure 3).
Table 1. Application examples of drug eluting balloon in arterial circulatory diseases.
Figure 3. Key findings of the drug-eluting balloon. The main points outlined in this graphic are: in coronary artery disease, the drug-eluting balloon is compressible, has no long-term irritation from metal stents, and is easy to manipulate in delicate areas; in renal artery disease, the drug-eluting balloon has been shown to have good therapeutic efficacy in renal artery atherosclerosis, renal arteritis, and renal arterial wall myofibrillar dysplasia; and in femoropopliteal artery disease, the drug-eluting balloon has resulted in improved postoperative patency and prevention of restenosis.
2.1 Applications in coronary artery lesions in situ
2.1.1 Minor coronary artery disease
Percutaneous coronary intervention (PCI) has emerged as the primary treatment modality for coronary artery disease (CAD) (70). However, the management of minor coronary artery lesions with a small vessel diameter (<2.8 mm) poses challenges due to technical limitations, resulting in high restenosis rates following treatment. Currently, there is an absence of suitable stents available for clinical use in these cases, making minor coronary artery disease a significant concern in clinical practice. Advancements in balloon technology have sparked increased interest in the use of drug-coated balloons (DCBs) for treating small coronary artery disease. DCBs offer advantages such as improved compressibility, absence of long-term metal stent irritation, and ease of manipulation at fine sites. The use of balloons allows for easy access to the lesion and effective dilation of stenotic vessels. Additionally, drugs carried by the balloons can be uniformly released over a short period, resulting in favorable therapeutic outcomes. A 6-month BELLO study conducted by Latib et al. in 2012 involved 182 patients with an average age exceeding 64 years (40). The study demonstrated that paclitaxel DCBs were associated with significantly lower restenosis rates and adverse cardiac events compared to patients treated with paclitaxel-eluting stents (DES). Nevertheless, it's important to note that the study's short observation period and small sample size only provide insights into the short-term efficacy of DCB treatment for small coronary artery disease. Contrasting these findings, Jeger et al. conducted a large-scale, long-term study involving 758 participants with an average age exceeding 65 years (41). Their results indicated similar rates of mid-cardiovascular adverse events between patients treated with DCBs and those treated with DES for small native coronary artery disease. Thus, suggesting that DCB treatment is not less effective than DES treatment. Further supporting the effectiveness and safety of DCBs in the treatment of small coronary artery disease, Cortese et al. conducted a 6-month clinical trial involving 232 elderly patients in Europe (42). The study demonstrated that paclitaxel DCBs were more effective than everolimus-eluting stents (EES). This was evidenced by significantly lower late lumen loss, as well as a reduced incidence of myocardial infarction and thrombosis in the DCB group. Researchers have also evaluated the therapeutic effects of combining drug balloons with other techniques. Unverdorben et al. compared the incidence of adverse cardiovascular events in 120 elderly German patients with coronary small vessel disease after DCB therapy or DCB + BMS therapy (43). Their findings suggested that DCB therapy alone was significantly superior to combined therapy, possibly due to the fact that bare-metal stents (BMS) stimulate the vessel wall and increase target cell blood flow reconstruction, hindering lesion healing.
2.1.2 Coronary artery bifurcation lesions
Coronary artery bifurcation lesions refer to the blockage of the coronary artery system at its bifurcation, which is a common form of coronary artery disease. The treatment of these lesions has been studied extensively over time. With the advancement of balloon technology, the use of balloons for treating bifurcation lesions is gaining attention. Authoritative organizations like the European Bifurcation Club and the International DEB Consensus Group have proposed the feasibility of percutaneous coronary intervention as a treatment method for coronary bifurcation disease (21, 71–73). Mathey et al. successfully treated 28 stable angina patients with coronary bifurcation lesions using paclitaxel DEB, with low incidence of adverse events. This suggests the feasibility of DEB for treating coronary bifurcation lesions. Another study conducted by Kleber FX included 128 patients over the age of 65, treated in Germany, and found the effectiveness of DEB for coronary bifurcation disease through the randomized multicenter PEPCAD-BIF trial (44, 45). However, the small sample sizes (28 and 64 patients) in both studies, including various lesion sites, limit the ability to draw definite conclusions. For left main trunk bifurcation lesions, Liu et al. observed lower incidence of adverse cardiovascular events in the DEB treatment group compared to the DES group in 85 patients. This suggests the effectiveness and safety of treating left main trunk bifurcation lesions solely with DEB (46). The importance of side branches becomes evident when the main coronary artery is blocked. Jing et al. studied DEB for treating coronary artery side branch bifurcation lesions and found that DEB was significantly more effective than conventional balloon angioplasty in 222 elderly patients (47). Therefore, drug balloons have shown effectiveness in treating both collateral and main coronary arteries with bifurcation lesions. Furthermore, combining directional coronary atherectomy with DEB angioplasty for bifurcation lesions in coronary arteries can yield positive clinical results with minimal branch damage, making it a potential stent-free percutaneous coronary intervention strategy (48). Overall, the use of drug balloons not only allows immediate opening of the bifurcation vessel but also reduces the occurrence of major adverse cardiovascular events, improving the long-term prognosis of patients (74).
2.1.3 Large coronary artery disease
Large coronary vessels (≥2.8 mm) encompass the right coronary artery, left anterior descending branch, and left circumflex branch. Coronary large vessel lesions represent a common form of coronary artery disease. These lesions, located within the coronary arteries, can manifest as diffuse, obstructive, or bifurcation lesions, highlighting the extensive involvement of large vessels. Consequently, research and treatment of large coronary vessels face numerous vascular limitations. With advancements in research techniques, an increasing number of studies have demonstrated the efficacy of drug-eluting balloons (DEB) in treating coronary large vessel lesions (75, 76). In a prospective study comparing patients with large and small coronary artery lesions after DEB treatment, the rate of major adverse cardiovascular events was lower in the large-vessel lesion group, with no reported fatalities (49). By dividing 234 patients with new-onset coronary artery disease into large-vessel and small-vessel groups based on vessel size and administering DEB treatment to both groups, Rosenberg et al. observed a target lesion revascularization rate of 3.8% in small vessels and 1.0% in large vessels after 9 months. The conclusion drawn was that DEB exhibited comparable therapeutic effects in both groups, with no statistically significant difference (50). Additionally, in a study conducted by Lu et al., 92 patients with an average age of 52 underwent DEB treatment for coronary macroangiopathy, yielding a major adverse cardiovascular event rate and target lesion revascularization rate of 4.3% in the short-term. These findings confirmed the safety and efficacy of DEB monotherapy for short-term treatment of coronary macroangiopathy. However, due to the limited observation period and small sample size, the confidence level of this conclusion was low (51). To investigate the long-term clinical effects of DEB, Wei et al. performed a randomized trial involving 100 patients with large coronary artery lesions who received either DEB or drug-eluting stents (DES). The late lumen loss and long-term incidence of major adverse cardiovascular events were monitored in both groups. Although the difference in late lumen loss between the two groups was marginal, DEB exhibited slightly superior distant positive vascular remodeling compared to DES (52). In a study by Hu et al., 119 patients with large-vessel lesions in coronary arteries, aged approximately 56 years on average, were followed up for 2 years to assess the incidence of adverse cardiovascular events. The patients were categorized into two groups: large-vessel bifurcation lesions and non-bifurcation lesions. The long-term follow-up revealed a low incidence of adverse cardiovascular events in both groups, indicating favorable long-term clinical outcomes of DEB-only treatment for large-vessel lesions in coronary arteries (53). The complex nature of large coronary artery disease has limited research in this area. While drug-eluting stents remain the primary clinical treatment for large vessel lesions, evidence suggests that DEB is a safe and effective alternative for treating large coronary artery disease, demonstrating promising short-term and long-term clinical efficacy.
2.1.4 Other in situ disease of the coronary arteries
Besides the aforementioned coronary artery diseases, drug-eluting balloons (DEB) are also utilized in the treatment of chronic total occlusive lesions, diffuse coronary artery disease, myocardial infarction, and other related conditions. Chronic total occlusion of the coronary arteries refers to the progressive narrowing of the arterial lumen, eventually leading to complete blockage. This condition is more prevalent in patients with coronary artery disease (CAD) (77), the safety of percutaneous coronary intervention has been established for chronic total occlusive coronary artery disease (78). In a study conducted in 2013, researchers exploring the efficacy of bare-metal stents (BMS) in treating chronic total occlusion observed that the combination of paclitaxel DEB treatment was more effective (79). Subsequently, Köln et al. followed up on 34 patients with an average age of 59 who underwent DEB treatment for chronic total occlusion. Through angiography, they found that DEB angioplasty, despite the absence of stent fixation, was a feasible and well-tolerated treatment option for chronic total occlusion of the coronary arteries in patients with good pre-expansion (54). According to the 2021 recommendations by the Asia-Pacific Consensus Panel for DEB treatment of coronary artery disease, DEB treatment is indicated for various cases, including chronic total occlusion of the coronary arteries (80), this establishes the feasibility of DEB in treating chronic total occlusive coronary artery disease.
Diffuse coronary artery disease was defined on coronary angiography as long coronary segments (≥20 mm) with angiographic irregularity in the absence of significant focal stenosis. It is an important determinant of the expected outcome of percutaneous coronary intervention (81). It can occur in distal coronary arteries, descending branches, side branches, and bifurcations, and its complexity results in a poorer outcome compared with focal lesions. The use of DES alone not only has long-term metal irritation and a higher risk of late thrombosis, but also the placement of long DES stents (≥60 mm) can lead to an increased incidence of adverse events, resulting in poorer outcomes in diffuse coronary artery disease, whereas the combination of DEB and DES can limit the length of the stent to a certain extent, reduce stent loading, and decrease the incidence of the aforementioned adverse events, providing a favorable treatment for diffuse coronary artery disease (82, 83).
Myocardial infarction, a serious disease associated with poor healing and commonly occurring as a complication of cardiovascular diseases, can be categorized into ST-segment elevation infarction, where vessels are mostly completely blocked, and non-ST-segment elevation infarction, where vessels are mostly incompletely blocked (55). Percutaneous coronary artery therapy is the primary treatment choice for myocardial infarction, and available studies indicate that DEB is safe and feasible in its treatment (56, 84). In a 2019 REVELATION study involving 120 middle-aged and elderly patients with acute myocardial infarction, Vos et al. compared the efficacy of DEB and drug-eluting stents (DES) in treating ST-segment elevation myocardial infarction. They found that the mean flow reserve fraction of patients in the DEB group was similar to that of the DES group, demonstrating that DEB was not inferior to DES in this regard (85). Later, Scheller et al. conducted a similar study comparing DEB, bare-metal stents (BMS), and second-generation DES in the treatment of non-ST-segment elevation myocardial infarction. The results also indicated non-inferiority for DEB, suggesting its feasibility and safety in treating both types of myocardial infarction (86). However, due to the limited number of studies on the use of DEB in myocardial infarction, further extensive research is required to establish its safety and efficacy. Additionally, drug-eluting balloons have demonstrated effectiveness in treating coronary artery disease in combination with diabetes mellitus, diffuse disease, and calcified lesions (57, 87, 88).
The minimally invasive nature of drug-eluting balloon implantation has led to its application in the treatment of cardiovascular disease in children. Children's coronary arteries are more prone to in-stent restenosis due to their smaller vessel diameters and higher percentage of lumen loss after stent implantation compared to adults. The long-term consequences of coronary stent implantation in children remain uncertain, thus opting for a “stent-less intervention” strategy seems more favorable for the long-term prognosis of pediatric patients. Wang et al. described a case involving a 16-year-old female patient who experienced a non-ST-segment elevation infarction caused by aortitis, and subsequently underwent drug-coated balloon angioplasty for in-stent restenosis that occurred one year after coronary stent implantation (58). Xu et al. reported the successful treatment of severe stenosis of the proximal left anterior descending coronary artery caused by Kawasaki disease in a 6-year-old boy using drug-coated balloon revascularization, demonstrating the feasibility of this treatment approach in children with Kawasaki disease (59). However, further investigation is needed to determine the safety and efficacy of drug-coated balloon treatment in this particular population. Hirose et al. initially described a male patient who underwent heart transplantation for restrictive cardiomyopathy at the age of 2 years and developed severe stenosis of the proximal left anterior descending coronary artery at the age of 11 years (60). Due to the rejection reaction, the transplanted cardiac population was more susceptible to restenosis compared to the general population. Nevertheless, no restenosis was observed during the 7-month follow-up period after undergoing angioplasty with drug-coated balloons, indicating the feasibility of using them in pediatric patients undergoing heart transplantation. However, as children represent a specialized group still in an important developmental phase, their vascular alignment, size, and tolerance to antiproliferative drugs differ significantly from those of adults. The long-term efficacy and safety of drug-coated balloons in pediatric cardiovascular disease have not yet been reported, thus further research is necessary to explore the long-term outcomes.
2.2 Applications in peripheral arterial system lesions
Peripheral artery disease (PAD) is a condition caused by atherosclerosis in non-cardiac blood vessels, with the femoral popliteal artery being the most commonly affected (89). The 2011 ESC treatment guidelines emphasize the importance of endovascular approaches, such as percutaneous transluminal angioplasty (PTA), for PAD management (90). However, due to the high restenosis rate associated with conventional treatments, scholars are increasingly focusing on the efficacy of drug-eluting balloons (DEBs) in peripheral arterial disease. In a large-scale study conducted by Kayssi et al. in 2016, DEB treatment was found to have a superior effect on lower extremity arterial patency and binary restenosis rates compared to conventional treatments (91). Nevertheless, it is worth noting that for more severe cases such as amputation, there is no significant evidence indicating a better treatment effect of DEBs. Comparative studies have shown that DEBs exhibit advantages over conventional angioplasty and drug-eluting stents (DES). For instance, a randomized trial by Tepe et al. demonstrated significantly higher patency rates in elderly patients with popliteal arteries treated with DEBs compared to those treated with conventional PTA (92). Similarly, the DRASTICO study conducted by Liistro et al. in 2019 revealed that both DEBs and DES were effective in treating high-risk femoropopliteal artery injuries, but DEBs did not show a significant advantage over DES (61). Consistent findings were reported by Bausback et al. in a clinical study involving 150 patients (62). These findings collectively suggest that DEBs offer improved treatment outcomes in femoropopliteal artery disease, enhancing patency and reducing restenosis risks.
The renal artery, as a crucial peripheral artery, commonly experiences stenosis in renal artery disease. Atherosclerotic renal artery stenosis is the most prevalent cause, followed by aortitis and myofibrillar dysplasia of the arterial wall (63). Stenting the renal artery can cause mechanical damage, leading to intimal disruption and subsequent smooth muscle cell and intimal proliferation, resulting in in-stent restenosis (ISR). Research has indicated that ISR exhibits more rapid smooth muscle cell proliferation than original plaque cells (64). In a study by Takahashi et al., which followed 1,052 patients treated with percutaneous transluminal renal artery angioplasty for renal artery stenosis, secondary stenting was associated with a significantly higher probability of restenosis compared to balloon dilation alone (65). Consequently, finding treatments that delay ISR onset while preserving the luminal diameter of the renal artery is an important task for scholars. Drug balloons have shown potential in reducing antiplatelet drug use and mitigating the inflammatory response in patients. Patients with renal stenosis associated with aortitis experience a high restenosis rate of up to 78% after renal angioplasty; however, drug balloons offer significant delays in restenosis (93). Notably, Yamamoto et al. reported a case of a patient with aortitis-induced renal artery stenosis who underwent multiple renal angioplasty treatments before achieving blood flow velocities similar to those after two years of drug balloon therapy (94). Similar outcomes were observed in five patients with aortitis who received pharmacological balloon treatment, as reported in another study (66). Nevertheless, further research is required to fully understand the efficacy of drug balloon therapy for aortitis-related renal artery stenosis. Restenosis rates remain high in stenting for renal artery stenosis after renal transplantation (TRAS), with reported incidences of 15% for bare metal stents and 15.7% for drug-eluting stents (67). The primary mechanism underlying TRAS-related restenosis is intimal hyperplasia, and drug balloons possess inherent advantages in directly targeting this condition. A retrospective study on 14 patients with TRAS treated with drug balloons indicated that the therapy was safe and effective in the short term, as there were no significant changes in creatinine and blood pressure indexes during a 6-month follow-up period (68). However, considering the limited number of patients included in this study and the lack of a control group receiving regular balloon treatments, further validation is needed to assess its long-term effects. Fibromuscular dysplasia (FMD), characterized by abnormal cell proliferation and structural variations in the arterial wall, is the second most common cause of renal artery stenosis (69). Due to insufficient available data, the therapeutic effect of pharmacological balloon therapy for FMD requires further exploration.
2.3 Application in in-stent restenosis lesions
In-stent restenosis refers to the reoccurrence of stenosis following the insertion of a stent in a narrowed blood vessel for dilation. The underlying mechanism primarily involves the long-term presence of the metallic stent as a foreign body within the arterial vasculature. This presence can induce changes in vascular wall stress and inflammation, leading to fibrin deposition, migration of fibroblasts, and neointimal hyperplasia, ultimately resulting in in-stent restenosis (95). Clinical experience indicates that reusing stents increases the likelihood of in-stent restenosis. However, drug-eluting balloons (DEB) offer an alternative approach. DEBs release anti-proliferative drugs during balloon dilatation without the need for permanent stent implantation. This allows for rapid drug delivery to the diseased vessel, promoting drug absorption and effectively preventing restenosis while protecting the intima. Compared to balloon-only or stent implantation strategies, DEB significantly reduces positive vascular remodeling and subsequent inflammatory responses. Consequently, DEB has been recommended as an effective treatment for in-stent restenosis in the 2014 ESC guidelines (12). There are two common clinical types of in-stent restenosis: bare-metal stent (BMS) in-stent restenosis and drug-eluting stent (DES) in-stent restenosis. Research on DEB for in-stent restenosis continues. A prospective study by a French scholar involving 206 elderly patients with DES in-stent restenosis found a low incidence of adverse cardiovascular events in patients treated with paclitaxel DEB (96). Virga et al. observed 39 patients with in-stent restenosis of the superficial femoral artery treated with DEB for 2 years, and they reported a high patency rate with only one death during the observation period (97). Similarly, Samady et al. found favorable long-term outcomes for DEB treatment of in-stent restenosis (98). Alfonso et al. conducted a randomized study on 189 elderly patients with BMS in-stent restenosis, comparing DEB treatment group and EES treatment group. The study revealed excellent treatment results in both groups, with a significantly lower recurrence rate (99). In the DAEDALUS study by Giacoppo et al. in 2020, which involved 710 elderly patients with BMS in-stent restenosis and 1,248 elderly patients with DES in-stent restenosis treated with DEB, the researchers found that DEB was effective in treating both types of in-stent restenosis mentioned above, but BMS in-stent restenosis had a better outcome than DES in-stent restenosis (100). Both DES in-stent restenosis and BES in-stent restenosis have a 10%–20% probability of recurrence (101), and their treatment is more challenging than primary stenosis. Recent studies have shown improved efficacy of DEB for recurrent in-stent restenosis, although differences still exist when compared to implantable fine DES (102, 103). The most effective treatment option for recurrent in-stent restenosis remains to be investigated, and the possibility of in-stent restenosis after DEB treatment cannot be ignored.
3 Drug eluting balloon application dilemma
3.1 Technical difficulties with drug-eluting balloons
Although numerous studies have demonstrated the therapeutic efficacy of drug-eluting balloons (DEB), and some countries and regions have included DEB as a medical device in their medical insurance coverage (Table 2), DEB still encounters several technical challenges. Firstly, the main therapeutic effect of DEB, which involves the use of anti-proliferative drugs such as Paclitaxel, is hindered by its cytotoxicity. Different drugs exhibit varying pharmacodynamic properties, and the efficiency of drug absorption by the vascular wall is negatively correlated with the lipid content of the wall. Consequently, diseases like atherosclerosis that increase the lipid content of the vascular wall also affect drug absorption efficiency. To counter this, DEB often employs drugs with higher lipophilicity, with Paclitaxel being the most commonly used anti-proliferative drug at present (104). But one study discovered that paclitaxel transportation is significantly impeded in the presence of thrombosis in blood vessels (105). Moreover, strict dose control is required for the use of Paclitaxel, generally within the range of 3–5 µg/mm2 (106). Lower doses decrease the antiproliferative effect on the vessel wall, while higher doses may cause cytotoxicity after prolonged exposure (107–109). Furthermore, Paclitaxel exhibits poor efficacy, a narrow therapeutic window, and low safety among various anti-proliferative drugs. Consequently, some studies have proposed the replacement of Paclitaxel with rapamycin, which offers similar anti-proliferative effects and a safer drug dosage. However, the inhibitory effect of rapamycin and its derivatives on intravascular lesions is still under investigation (18, 104). Additionally, Wessely et al. found that when comparing the performance of Paclitaxel and rapamycin on drug-eluting stents (DES), rapamycin resulted in a higher restenosis rate and significantly greater late lumen loss (110). Similarly, Alfonso et al. compared the efficacy of Paclitaxel and everolimus in treating patients with in-stent restenosis and found that everolimus was significantly more effective than Paclitaxel (111). Although Paclitaxel carries a risk of cytotoxicity, the drug balloon used in clinical practice is a finished product that does not require physicians to control the drug dosage. Consequently, the clinical manifestation of Paclitaxel cytotoxicity is reduced, thus promoting its use in clinics, despite it not being the optimal choice. Secondly, the selection of excipients is crucial. Currently, anti-proliferative drugs in DEB are typically used in combination with excipients to minimize drug loss during balloon transport. Common excipients include hydrophilic substances such as urea and iopromide. While highly hydrophilic substances effectively prevent the loss of highly lipophilic drugs during transport, some studies have indicated that urea and iopromide tend to shed their coating when transported within the vasculature for extended periods. This shedding increases the rate of drug loss and diminishes efficacy (35, 112, 113). Lastly, apart from optimizing Paclitaxel drugs and excipients, precise control of balloon dilation pressure is also essential. Animal experiments conducted by Stolzenburg et al. demonstrated that higher inflation pressure promotes the transfer of Paclitaxel in atherosclerosis (114). However, excessive inflation pressure can lead to plaque rupture, aggravate vascular injury, increase the risk of vascular dissection, and cause in-stent restenosis. Conversely, low inflation pressure results in insufficient contact between the balloon and the vessel wall, reducing drug efficacy. While prolonging the contact time between the balloon and the vessel wall can enhance drug absorption, it also increases the risk of vascular injury (115, 116). Consequently, resolving the issues associated with balloon expansion pressure and achieving optimal contact time between the balloon and the vessel wall has become a recent focus of research. Numerous micron and nano new materials may offer potential solutions to this problem.
Table 2. Approval of vascular DEB medical devices in some countries.
3.2 Drug eluting balloon complication management
DEB, a novel balloon technology, offers significant advantages in the treatment of arterial circulatory disorders. However, it's important to acknowledge that complications such as microthrombosis and vascular dissection can occur during its utilization. Despite being infrequent, these complications cannot be disregarded considering their serious consequences. The combination of lipophilic antiproliferative drugs with hydrophilic excipients holds the potential for producing a highly crystalline coating that is unstable and prone to particle formation during crystallization. Particularly, the combination of highly hydrophilic excipients like urea and iopromide with lipophilic drugs such as paclitaxel can lead to easier dissolution of the coating during balloon transport, resulting in the formation of numerous particles. This occurrence is especially prevalent during balloon expansion, which increases the risk of emboli formation when these particles reach downstream vessels (112, 117). Kelsch et al. observed in an animal model that at least 25%–35% of the paclitaxel drug was shed and thrombotic occlusion was observed during the entry of DEB with urea and iopromide as excipients into the vasculature to the site of lesion initiation (118). To address this issue, Gongora CA proposed the use of a more hydrophobic excipient like BTHC to enhance the integrity of the balloon coating, subsequently reducing particulate production. In their investigation, they compared three different DEB technologies—paclitaxel urea DEB, paclitaxel polysorbate DEB, and paclitaxel BTHC DEB—in a porcine model. The results demonstrated that paclitaxel BTHC DEB produced nearly ten times fewer particles compared to paclitaxel urea DEB and paclitaxel polysorbate DEB (119). In addition to employing more hydrophobic excipients for minimizing particulate production, alternative methods have been proposed. One such method involves placing the drug and excipient within a folded balloon, reducing the exposed area of the drug coating during transport. Once the balloon reaches the lesion site, it expands fully to ensure complete drug exposure (11). These two improved methods are currently under investigation. Whether a more hydrophobic excipient or a folded balloon approach is chosen, it is evident that a high level of technological proficiency is required. However, questions regarding the potential delayed release of the drug upon contact with the vessel wall and the ability to accurately release the drug still necessitate further confirmation through additional studies.
Since pre-dilatation of the vessel is necessary before using DEB, it is essential to consider the impact of DEB being stent-free. In cases where pre-dilatation is insufficient, the vessel may lose stenting support and experience vascular elastic retraction. Conversely, excessive pre-dilatation can lead to vessel dissection, resulting in restricted blood flow (120, 121). Balloon angioplasty functions by stretching atherosclerotic arteries, which often causes vascular injury leading to dissection (122). The anatomical structure of coronary arteries typically comprises intima, media, and adventitia. Arterial dissection occurs when layers of the arterial wall separate, forming a false lumen between the intima and media or between the media and adventitia (123). Separation of the epicardium is accompanied by the formation of a false lumen, and this stripping reduces or obstructs blood flow, which reduces the rate of recanalization of the target diseased vessel at the site of the lesion, making healing very difficult, and if the entrapment remains untreated for a long period of time, it can lead to endothelial hyperplasia and restenosis due to prolongation of the inflammatory process (124, 125). In contrast, in a THUNDER study it was found that treatment with DEB PCI did not require implantation of a stent as long as the entrapment does not lead to acute blood flow restriction, stent implantation is not required (126). According to the Delphi Expert Consensus, stenting is recommended for post-balloon angioplasty dissection in cases involving reduced lesion vessel diameter, impaired blood flow, or poor morphology (127). The Tack Endovascular System (Intact Vascular, Wayne, Pennsylvania) is a novel device that has been utilized by Gray WA to treat 213 patients and assess dissection repair outcomes. The study confirmed the safety and efficacy of the Tack Endovascular System in focal dissection repair (128). Furthermore, Kobayashi N observed 319 elderly patients with vascular dissection in the femoropopliteal artery and found higher restenosis rates in patients with severe dissection. This finding suggests that the generation of vascular dissection may be a significant factor contributing to in-stent restenosis occurrence (129). Currently, BMS in-stent restenosis and DES in-stent restenosis are common occurrences, with neointimal hyperplasia and vascular retraction being mechanisms associated with in-stent restenosis. This is especially prominent in patients with diabetes and inflammation (130). Although DEB use has shown a reduction in the incidence of in-stent restenosis, it is not entirely avoided. Some studies have unveiled that DEB is less effective than repositioning DES for treating restenosis caused by DES (100, 131). However, this challenge can potentially be addressed through the combination of DEB with biodegradable stents. Such a combination eliminates the need for permanent stent placement, and the use of biodegradable stents can prevent short-term vessel elastic retraction effectively, consequently reducing late in-stent restenosis (75). Currently, DEB combined with DES is the predominant approach in clinical practice, while BMS is rarely used due to its strong irritation of the vessel wall. There is limited research on the combined use of both techniques, and the safety and efficacy of such combinations require further investigation.
Observation of disease after DEB treatment can be used as a means to assess disease healing. Invasive and non-invasive methods are usually available, and the commonly used invasive methods include coronary angiography and optical coherence tomography. Coronary angiography can be used to compare the changes in vessel patency and stenosis before and after treatment, and can be used for localized treatment (132, 133). Optical coherence tomography is a new type of catheter-based invasive imaging modality, which uses infrared light rather than ultrasound, and can clearly reflect arterial plaques and blood clots (134). Non-invasive methods include intravascular ultrasound, coronary CT, and cardiac magnetic resonance. Intravascular ultrasound used to be the gold standard for evaluating stent placement and stent-vessel response, and it can use ultrasound to determine the structure of the vascular lumen as well as blood flow, but it has the disadvantages of more stenting artifacts and inability to distinguish small neoplastic endothelial tissues (135, 136). Overall, both types of assessment methods have their own advantages, and clinical use should be based on the patient's condition to choose the appropriate assessment method.
4 Conclusion
Drug-eluting balloons, as a new interventional technique, can avoid the hazards associated with stent implantation. There have been numerous clinical trials demonstrating the safety and efficacy of drug-eluting balloons in the treatment of coronary artery disease and lower extremity artery disease, and they are expected to be used in larger vessel and peripheral vascular diseases. There are also a large number of trials comparing drug-eluting balloons with other interventional techniques that demonstrate the advantages of drug-eluting balloons in maintaining vessel patency and reducing the rate of in-stent restenosis. However, the current studies on drug-eluting balloons are characterized by small sample size and short observation time, and the technical shortcomings in the clinical use of drug-eluting balloons may lead to adverse conditions such as particulate matter and vessel dissection, therefore, more studies on the safety of drug-eluting balloons are needed. By reviewing the progress of drug-eluting balloon research mentioned above, we can provide new ideas for the treatment of more arterial system diseases.
Author contributions
KL: Writing – review & editing, Writing – original draft. YC: Writing – review & editing, Writing – original draft. XY: Writing – review & editing, Writing – original draft. MG: Writing – review & editing. PW: Writing – original draft, Writing – review & editing. BX: Writing – review & editing. ML: Writing – review & editing. ZT: Writing – review & editing. JH: Writing – review & editing. KP: Writing – review & editing. HP: Writing – review & editing, Writing – original draft.
Funding
The author(s) declare that financial support was received for the research, authorship, and/or publication of this article.
This work was supported by Key Projects of Hospital Management of the General Hospital of the Western Theater Command of PLA (2021-XZYG-A03), Tianfu Qingcheng Project-Tianfu Science and Technology Elite (No. 1358), The General Hospital of Western Theater Command-Spark Young Innovative Talents (to HaifengPei) and The National Natural Science Foundation of China (81970241).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Yuan Y, Li SM, Zhu FS, Zhi XL, Ji XM. Correlative study of carotid transient ischemic attacks and intracranial or extracranial angiostenosis. Zhong Nan Da Xue Xue Bao Yi Xue Ban. (2008) 33:751–4.18772519
2. Xu X, Na N, Pan X, Wang K, Ma A, Wang Y, et al. Association of TLR4 gene polymorphisms with large artery atherosclerotic stroke and vascular bed selectivity of atherosclerotic lesions. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. (2014) 31:455–61. doi: 10.3760/cma.j.issn.1003-9406.2014.04.009
3. Dotter CT, Judkins MP. Transluminal treatment of arteriosclerotic obstruction. Description of a new technic and a preliminary report of its application. Circulation. (1964) 30:654–70. doi: 10.1161/01.cir.30.5.654
4. Gruntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med. (1979) 301:61–8. doi: 10.1056/NEJM197907123010201
5. Louis EL, Provan JL, Gray RR, Grosman H, Ameli FM, Elliott DS. Percutaneous transluminal angioplasty in peripheral vascular disease: a review. Can Fam Physician. (1982) 28:291–4.21286052
6. Gruntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet. (1978) 1:263. doi: 10.1016/s0140-6736(78)90500-7
7. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med. (1987) 316:701–6. doi: 10.1056/NEJM198703193161201
8. Liistro F, Colombo A. Late acute thrombosis after paclitaxel eluting stent implantation. Heart. (2001) 86:262–4. doi: 10.1136/heart.86.3.262
9. Rensing BJ, Vos J, Smits PC, Foley DP, van den Brand MJ, van der Giessen WJ, et al. Coronary restenosis elimination with a sirolimus eluting stent: first European human experience with 6-month angiographic and intravascular ultrasonic follow-up. Eur Heart J. (2001) 22:2125–30. doi: 10.1053/euhj.2001.2892
10. Scheller B, Speck U, Schmitt A, Bohm M, Nickenig G. Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation. J Am Coll Cardiol. (2003) 42:1415–20. doi: 10.1016/s0735-1097(03)01056-8
11. Scheller B, Speck U, Abramjuk C, Bernhardt U, Bohm M, Nickenig G. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation. (2004) 110:810–4. doi: 10.1161/01.CIR.0000138929.71660.E0
12. Authors/Task Force members, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, et al. 2014 ESC/EACTS guidelines on myocardial revascularization: the task force on myocardial revascularization of the European society of cardiology (ESC) and the European association for cardio-thoracic surgery (EACTS)Developed with the special contribution of the European association of percutaneous cardiovascular interventions (EAPCI). Eur Heart J. (2014) 35:2541–619. doi: 10.1093/eurheartj/ehu278
13. Gertz ZM, Wilensky RL. Local drug delivery for treatment of coronary and peripheral artery disease. Cardiovasc Ther. (2011) 29:e54–66. doi: 10.1111/j.1755-5922.2010.00187.x
14. Petersen S, Kaule S, Stein F, Minrath I, Schmitz KP, Kragl U, et al. Novel paclitaxel-coated angioplasty balloon catheter based on cetylpyridinium salicylate: preparation, characterization and simulated use in an in vitro vessel model. Mater Sci Eng C Mater Biol Appl. (2013) 33:4244–50. doi: 10.1016/j.msec.2013.06.021
15. Dugas TR, Brewer G, Longwell M, Fradella T, Braun J, Astete CE, et al. Nanoentrapped polyphenol coating for sustained drug release from a balloon catheter. J Biomed Mater Res B Appl Biomater. (2019) 107:646–51. doi: 10.1002/jbm.b.34157
16. Rykowska I, Nowak I, Nowak R. Drug-eluting stents and balloons-materials, structure designs, and coating techniques: a review. Molecules. (2020) 25:4624. doi: 10.3390/molecules25204624
17. Ang H, Koppara TR, Cassese S, Ng J, Joner M, Foin N. Drug-coated balloons: technical and clinical progress. Vasc Med. (2020) 25:577–87. doi: 10.1177/1358863X20927791
18. Xiong GM, Ang H, Lin J, Lui YS, Phua JL, Chan JN, et al. Materials technology in drug eluting balloons: current and future perspectives. J Control Release. (2016) 239:92–106. doi: 10.1016/j.jconrel.2016.08.018
19. Cortese B, Caiazzo G, Di Palma G, De Rosa S. Comparison between sirolimus- and paclitaxel-coated balloon for revascularization of coronary arteries: the SIRPAC (SIRolimus-PAClitaxel) study. Cardiovasc Revasc Med. (2021) 28:1–6. doi: 10.1016/j.carrev.2021.04.013
20. Zou W, Cao G, Xi Y, Zhang N. New approach for local delivery of rapamycin by bioadhesive PLGA-carbopol nanoparticles. Drug Deliv. (2009) 16:15–23. doi: 10.1080/10717540802481307
21. Jeger RV, Eccleshall S, Wan Ahmad WA, Ge J, Poerner TC, Shin ES, et al. Drug-coated balloons for coronary artery disease: third report of the international DCB consensus group. JACC Cardiovasc Interv. (2020) 13:1391–402. doi: 10.1016/j.jcin.2020.02.043
22. Lee K, Lee SG, Jang I, Park SH, Yang D, Seo IH, et al. Linear micro-patterned drug eluting balloon (LMDEB) for enhanced endovascular drug delivery. Sci Rep. (2018) 8:3666. doi: 10.1038/s41598-018-21649-7
23. Lee K, Lee J, Lee SG, Park S, Yang DS, Lee JJ, et al. Microneedle drug eluting balloon for enhanced drug delivery to vascular tissue. J Control Release. (2020) 321:174–83. doi: 10.1016/j.jconrel.2020.02.012
24. Zhang T, Guo G, Yang L, Wang Y. An ultralow dose paclitaxel coated drug balloon with an outer protective sheath for peripheral arterial disease treatment. J Mater Chem B. (2021) 9:2428–35. doi: 10.1039/d0tb02720k
25. Bukka M, Rednam PJ, Sinha M. Drug-eluting balloon: design, technology and clinical aspects. Biomed Mater. (2018) 13:032001. doi: 10.1088/1748-605X/aaa0aa
26. Posa A, Nyolczas N, Hemetsberger R, Pavo N, Petnehazy O, Petrasi Z, et al. Optimization of drug-eluting balloon use for safety and efficacy: evaluation of the 2nd generation paclitaxel-eluting DIOR-balloon in porcine coronary arteries. Catheter Cardiovasc Interv. (2010) 76:395–403. doi: 10.1002/ccd.22468
27. Cortese B, Bertoletti A. Paclitaxel coated balloons for coronary artery interventions: a comprehensive review of preclinical and clinical data. Int J Cardiol. (2012) 161:4–12. doi: 10.1016/j.ijcard.2011.08.855
28. Gruber P, Braun C, Kahles T, Hlavica M, Anon J, Diepers M, et al. Percutaneous transluminal angioplasty using the novel drug-coated balloon catheter SeQuent Please NEO for the treatment of symptomatic intracranial severe stenosis: feasibility and safety study. J Neurointerv Surg. (2019) 11:719–22. doi: 10.1136/neurintsurg-2018-014378
29. Torii S, Kolodgie FD, Virmani R, Finn AV. IN.PACT admiral drug-coated balloons in peripheral artery disease: current perspectives. Med Devices (Auckl). (2019) 12:53–64. doi: 10.2147/MDER.S165620
30. Peterson S, Hasenbank M, Silvestro C, Raina SIN. PACT Admiral drug-coated balloon: durable, consistent and safe treatment for femoropopliteal peripheral artery disease. Adv Drug Deliv Rev. (2017) 112:69–77. doi: 10.1016/j.addr.2016.10.003
31. Jordan MA, Toso RJ, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci U S A. (1993) 90:9552–6. doi: 10.1073/pnas.90.20.9552
32. Yang CH, Horwitz SB. Taxol((R)): the first microtubule stabilizing agent. Int J Mol Sci. (2017) 18:1733. doi: 10.3390/ijms18081733
33. Li J, Kim SG, Blenis J. Rapamycin: one drug, many effects. Cell Metab. (2014) 19:373–9. doi: 10.1016/j.cmet.2014.01.001
34. Palmerini T, Benedetto U, Biondi-Zoccai G, Della Riva D, Bacchi-Reggiani L, Smits PC, et al. Long-term safety of drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol. (2015) 65:2496–507. doi: 10.1016/j.jacc.2015.04.017
35. Marlevi D, Edelman ER. Vascular lesion-specific drug delivery systems: JACC state-of-the-art review. J Am Coll Cardiol. (2021) 77:2413–31. doi: 10.1016/j.jacc.2021.03.307
36. Scheller B. Opportunities and limitations of drug-coated balloons in interventional therapies. Herz. (2011) 36:232–9. doi: 10.1007/s00059-011-3462-3
37. Belkacemi A, Agostoni P, Nathoe HM, Voskuil M, Shao C, Van Belle E, et al. First results of the DEB-AMI (drug eluting balloon in acute ST-segment elevation myocardial infarction) trial: a multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in primary percutaneous coronary intervention with 6-month angiographic, intravascular, functional, and clinical outcomes. J Am Coll Cardiol. (2012) 59:2327–37. doi: 10.1016/j.jacc.2012.02.027
38. Januszek R, Bil J, Gilis-Malinowska N, Staszczak B, Figatowski T, Milewski M, et al. Long-term outcomes following drug-eluting balloon or thin-strut drug-eluting stents for treatment of in-stent restenosis stratified by duration of dual antiplatelet therapy (DEB-dragon registry). Postepy Kardiol Interwencyjnej. (2022) 18:14–26. doi: 10.5114/aic.2022.115631
39. Laksono S, Setianto B, Surya SP. Drug-eluting balloon: is it useful? Egypt Heart J. (2020) 72:80. doi: 10.1186/s43044-020-00116-7
40. Latib A, Colombo A, Castriota F, Micari A, Cremonesi A, De Felice F, et al. A randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels: the BELLO (balloon elution and late loss optimization) study. J Am Coll Cardiol. (2012) 60:2473–80. doi: 10.1016/j.jacc.2012.09.020
41. Jeger RV, Farah A, Ohlow MA, Mangner N, Mobius-Winkler S, Leibundgut G, et al. Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial. Lancet. (2018) 392:849–56. doi: 10.1016/S0140-6736(18)31719-7
42. Cortese B, Di Palma G, Guimaraes MG, Piraino D, Orrego PS, Buccheri D, et al. Drug-coated balloon versus drug-eluting stent for small coronary vessel disease: PICCOLETO II randomized clinical trial. JACC Cardiovasc Interv. (2020) 13:2840–49. doi: 10.1016/j.jcin.2020.08.035
43. Unverdorben M, Kleber FX, Heuer H, Figulla HR, Vallbracht C, Leschke M, et al. Treatment of small coronary arteries with a paclitaxel-coated balloon catheter in the PEPCAD I study: are lesions clinically stable from 12 to 36 months? EuroIntervention. (2013) 9:620–8. doi: 10.4244/EIJV9I5A99
44. Mathey DG, Wendig I, Boxberger M, Bonaventura K, Kleber FX. Treatment of bifurcation lesions with a drug-eluting balloon: the PEPCAD V (paclitaxel eluting PTCA balloon in coronary artery disease) trial. EuroIntervention. (2011) 7(Suppl K):K61–5. doi: 10.4244/EIJV7SKA11
45. Kleber FX, Rittger H, Ludwig J, Schulz A, Mathey DG, Boxberger M, et al. Drug eluting balloons as stand alone procedure for coronary bifurcational lesions: results of the randomized multicenter PEPCAD-BIF trial. Clin Res Cardiol. (2016) 105:613–21. doi: 10.1007/s00392-015-0957-6
46. Liu H, Zhao Y, Lu Y, Zhou S, Zhang Y, Zhao J, et al. The drug coated balloon-only strategy for treatment of de novo left main coronary artery bifurcation lesion: stentless strategy. Clin Appl Thromb Hemost. (2022) 28:10760296221118489. doi: 10.1177/10760296221118489
47. Jing QM, Zhao X, Han YL, Gao LL, Zheng Y, Li ZQ, et al. A drug-eluting balloon for the treatment of coronary bifurcation lesions in the side branch: a prospective multicenter randomized (BEYOND) clinical trial in China. Chin Med J (Engl). (2020) 133:899–908. doi: 10.1097/CM9.0000000000000743
48. Kitani S, Igarashi Y, Tsuchikane E, Nakamura S, Seino Y, Habara M, et al. Efficacy of drug-coated balloon angioplasty after directional coronary atherectomy for coronary bifurcation lesions (DCA/DCB registry). Catheter Cardiovasc Interv. (2021) 97:E614–E623. doi: 10.1002/ccd.29185
49. Yu X, Ji F, Xu F, Zhang W, Wang X, Lu D, et al. Efficacy of paclitaxel coated balloon in the treatment of primary coronary artery lesions with a diameter of 2.8 mm and above. Chin J Cardiovasc Dis. (2018) 46:32–8. doi: 10.3760/cma.j.issn.0253-3758.2018.01.006
50. Rosenberg M, Waliszewski M, Krackhardt F, Chin K, Wan Ahmad WA, Caramanno G, et al. Drug coated balloon-only strategy in de novo lesions of large coronary vessels. J Interv Cardiol. (2019) 2019:6548696. doi: 10.1155/2019/6548696
51. Lu W, Zhu Y, Han Z, Sun G, Qin X, Wang Z, et al. Short-term outcomes from drug-coated balloon for coronary de novo lesions in large vessels. J Cardiol. (2019) 73:151–5. doi: 10.1016/j.jjcc.2018.07.008
52. Wei X, Wang X, Zhao T, Lin Y, Chen B, D. o. C. M., the Fifth Affiliated Hospital of Sun Yat sen University. Efficacy and safety of paclitaxel coated balloon in the treatment of primary coronary artery disease. Chin J Atherosclerosis. (2019) 27:150–5.
53. Hu FW, Chang S, Li Q, Zhu YX, Wang XY, Cheng YW, et al. Long-term clinical outcomes after percutaneous coronary intervention with drug-coated balloon-only strategy in de novo lesions of large coronary arteries. Front Cardiovasc Med. (2022) 9:882303. doi: 10.3389/fcvm.2022.882303
54. Koln PJ, Scheller B, Liew HB, Rissanen TT, Ahmad WA, Weser R, et al. Treatment of chronic total occlusions in native coronary arteries by drug-coated balloons without stenting—a feasibility and safety study. Int J Cardiol. (2016) 225:262–7. doi: 10.1016/j.ijcard.2016.09.105
55. Mitsis A, Gragnano F. Myocardial infarction with and without ST-segment elevation: a contemporary reappraisal of similarities and differences. Curr Cardiol Rev. (2021) 17:e230421189013. doi: 10.2174/1573403X16999201210195702
56. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. (2003) 361:13–20. doi: 10.1016/S0140-6736(03)12113-7
57. Sabate M. Drug-coated balloon for diabetic patients with small coronary vessels: is it the way to go? JACC Cardiovasc Interv. (2021) 14:1799–800. doi: 10.1016/j.jcin.2021.07.011
58. Wang Y, Duan Y, Su H, Wang Y, Bai W, Chen H, et al. Acute non-ST segment elevation myocardial infarction as the first manifestation of Takayasu arteritis in a 16-year-old female patient: a case report and literature review. J Int Med Res. (2023) 51:3000605231178599. doi: 10.1177/03000605231178599
59. Xu X, Jin S, Liu T. Drug-coated balloon angioplasty for coronary stenotic lesions in a paediatric patient after Kawasaki disease. Cardiol Young. (2022) 32:340–2. doi: 10.1017/S104795112100295X
60. Hirose M, Narita J, Hashimoto K, Ishii R, Ishida H, Ozono K. Use of drug-coated balloon instead of drug-eluting stent for pediatric cardiac allograft vasculopathy. Ann Pediatr Cardiol. (2023) 16:45–7. doi: 10.4103/apc.apc_47_22
61. Liistro F, Angioli P, Porto I, Ducci K, Falsini G, Ventoruzzo G, et al. Drug-eluting balloon versus drug-eluting stent for complex femoropopliteal arterial lesions: the DRASTICO study. J Am Coll Cardiol. (2019) 74:205–15. doi: 10.1016/j.jacc.2019.04.057
62. Bausback Y, Wittig T, Schmidt A, Zeller T, Bosiers M, Peeters P, et al. Drug-eluting stent versus drug-coated balloon revascularization in patients with femoropopliteal arterial disease. J Am Coll Cardiol. (2019) 73:667–9. doi: 10.1016/j.jacc.2018.11.039
63. Voiculescu A, Grabensee B, Jung G, Modder U, Sandmann W. Renovascular disease: a review of diagnostic and therapeutic procedures. Minerva Urol Nefrol. (2006) 58:127–49.17124483
64. Prati F, Di Mario C, Moussa I, Reimers B, Mallus MT, Parma A, et al. In-stent neointimal proliferation correlates with the amount of residual plaque burden outside the stent: an intravascular ultrasound study. Circulation. (1999) 99:1011–4. doi: 10.1161/01.cir.99.8.1011
65. Takahashi EA, McKusick MA, Bjarnason H, Piryani A, Harmsen WS, Misra S. Treatment of in-stent restenosis in patients with renal artery stenosis. J Vasc Interv Radiol. (2016) 27:1657–62. doi: 10.1016/j.jvir.2016.05.041
66. Bi YH, Ren JZ, Yi MF, Li JD, Han XW. Drug coated balloon angioplasty for renal artery stenosis due to Takayasu arteritis: report of five cases. World J Clin Cases. (2019) 7:2888–93. doi: 10.12998/wjcc.v7.i18.2888
67. Ngo AT, Markar SR, De Lijster MS, Duncan N, Taube D, Hamady MS. A systematic review of outcomes following percutaneous transluminal angioplasty and stenting in the treatment of transplant renal artery stenosis. Cardiovasc Intervent Radiol. (2015) 38:1573–88. doi: 10.1007/s00270-015-1134-z
68. Ding M, Feng N, Tang D, Feng J, Li Z, Jia M, et al. Melatonin prevents Drp1-mediated mitochondrial fission in diabetic hearts through SIRT1-PGC1alpha pathway. J Pineal Res. (2018) 65:e 12491. doi: 10.1111/jpi.12491
69. Kozlova EV, Bulkina OS, Lopukhova VV, Mironov VM, Kushnir VV, Vasilenko EI, et al. Management of the patient with renal artery fibromuscular dysplasia: clinical case. Kardiologiia. (2022) 62:65–8. doi: 10.18087/cardio.2022.8.n2069
70. Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, Applegate R, et al. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation. (2009) 119:3198–206. doi: 10.1161/CIRCULATIONAHA.108.826479
71. Lassen JF, Holm NR, Stankovic G, Lefevre T, Chieffo A, Hildick-Smith D, et al. Percutaneous coronary intervention for coronary bifurcation disease: consensus from the first 10 years of the European bifurcation club meetings. EuroIntervention. (2014) 10:545–60. doi: 10.4244/EIJV10I5A97
72. Hildick-Smith D, Arunothayaraj S, Stankovic G, Chen SL. Percutaneous coronary intervention of bifurcation lesions. EuroIntervention. (2022) 18:e273–91. doi: 10.4244/EIJ-D-21-01065
73. Burzotta F, Lassen JF, Lefevre T, Banning AP, Chatzizisis YS, Johnson TW, et al. Percutaneous coronary intervention for bifurcation coronary lesions: the 15(th) consensus document from the European bifurcation club. EuroIntervention. (2021) 16:1307–17. doi: 10.4244/EIJ-D-20-00169
74. Piraino D, Cortese B, Buccheri D, Dendramis G, Andolina G. Healing after coronary artery dissection: the effect of a drug coated balloon angioplasty in a bifurcation lesion. A lesson from intravascular ultrasound analysis. Int J Cardiol. (2016) 203:298–300. doi: 10.1016/j.ijcard.2015.10.156
75. Piraino D, Carella M, Buccheri D, Andolina G. Bifurcation lesions: bioresorbable vascular scaffold and drug coated balloon, an efficacy association. Lessons from optimal coherence tomography. Int J Cardiol. (2016) 212:92–3. doi: 10.1016/j.ijcard.2016.03.048
76. Yu X, Ji FS, Xu F, Zhang WD, Wang XY, Lu D, et al. Therapeutic efficacy of paclitaxel-coated balloon for de novo coronary lesions with diameters larger than 2.8 mm. Zhonghua Xin Xue Guan Bing Za Zhi. (2018) 46:32–8. doi: 10.3760/cma.j.issn.0253-3758.2018.01.006
77. Galla JM, Whitlow PL. Coronary chronic total occlusion. Cardiol Clin. (2010) 28:71–9. doi: 10.1016/j.ccl.2009.10.003
78. Yoneda K, Takahashi T, Kishi K. Over ten years’ follow-up of chronic total coronary occlusion angioplasty. Cardiovasc Revasc Med. (2021) 25:44–6. doi: 10.1016/j.carrev.2020.10.013
79. Wohrle J, Werner GS. Paclitaxel-coated balloon with bare-metal stenting in patients with chronic total occlusions in native coronary arteries. Catheter Cardiovasc Interv. (2013) 81:793–9. doi: 10.1002/ccd.24409
80. Her AY, Shin ES, Bang LH, Nuruddin AA, Tang Q, Hsieh IC, et al. Drug-coated balloon treatment in coronary artery disease: recommendations from an Asia-Pacific consensus group. Cardiol J. (2021) 28:136–49. doi: 10.5603/CJ.a2019.0093
81. Ielasi A, Buono A, Pellicano M, Tedeschi D, Loffi M, Donahue M, et al. A hybrid approach evaluating a drug-coated balloon in combination with a new-generation drug-eluting stent in the treatment of de novo diffuse coronary artery disease: the HYPER pilot study. Cardiovasc Revasc Med. (2021) 28:14–9. doi: 10.1016/j.carrev.2020.07.036
82. Gitto M, Sticchi A, Chiarito M, Novelli L, Leone PP, Mincione G, et al. Drug-coated balloon angioplasty for de novo lesions on the left anterior descending artery. Circ Cardiovasc Interv. (2023) 16:e 013232. doi: 10.1161/CIRCINTERVENTIONS.123.013232
83. Scarsini R, Fezzi S, Leone AM, De Maria GL, Pighi M, Marcoli M, et al. Functional patterns of coronary disease: diffuse, focal, and serial lesions. JACC Cardiovasc Interv. (2022) 15:2174–91. doi: 10.1016/j.jcin.2022.07.015
84. Ho HH, Tan J, Ooi YW, Loh KK, Aung TH, Yin NT, et al. Preliminary experience with drug-coated balloon angioplasty in primary percutaneous coronary intervention. World J Cardiol. (2015) 7:311–4. doi: 10.4330/wjc.v7.i6.311
85. Vos NS, Fagel ND, Amoroso G, Herrman JR, Patterson MS, Piers LH, et al. Paclitaxel-coated balloon angioplasty versus drug-eluting stent in acute myocardial infarction: the revelation randomized trial. JACC Cardiovasc Interv. (2019) 12:1691–9. doi: 10.1016/j.jcin.2019.04.016
86. Scheller B, Ohlow MA, Ewen S, Kische S, Rudolph TK, Clever YP, et al. Bare metal or drug-eluting stent versus drug-coated balloon in non-ST-elevation myocardial infarction: the randomised PEPCAD NSTEMI trial. EuroIntervention. (2020) 15:1527–33. doi: 10.4244/EIJ-D-19-00723
87. Rissanen TT, Uskela S, Siljander A, Karkkainen JM, Mantyla P, Mustonen J, et al. Percutaneous coronary intervention of complex calcified lesions with drug-coated balloon after rotational atherectomy. J Interv Cardiol. (2017) 30:139–46. doi: 10.1111/joic.12366
88. Basavarajaiah S, Latib A, Shannon J, Naganuma T, Sticchi A, Bertoldi L, et al. Drug-eluting balloon in the treatment of in-stent restenosis and diffuse coronary artery disease: real-world experience from our registry. J Interv Cardiol. (2014) 27:348–55. doi: 10.1111/joic.12129
89. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. Tasc II working group. inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. (2007) 45(Suppl S):S5–67. doi: 10.1016/j.jvs.2006.12.037
90. Stroke O E, Tendera M, Aboyans V, Bartelink ML, Baumgartner I, Clement D, et al. ESC guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the task force on the diagnosis and treatment of peripheral artery diseases of the European society of cardiology (ESC). Eur Heart J. (2011) 32:2851–906. doi: 10.1093/eurheartj/ehr211
91. Kayssi A, Al-Atassi T, Oreopoulos G, Roche-Nagle G, Tan KT, Rajan DK. Drug-eluting balloon angioplasty versus uncoated balloon angioplasty for peripheral arterial disease of the lower limbs. Cochrane Database Syst Rev. (2016) 2016:CD011319. doi: 10.1002/14651858.CD011319.pub2
92. Tepe G, Laird J, Schneider P, Brodmann M, Krishnan P, Micari A, et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. (2015) 131:495–502. doi: 10.1161/CIRCULATIONAHA.114.011004
93. Yoshida M, Kimura A, Katsuragi K, Numano F, Sasazuki T. DNA typing of HLA-B gene in Takayasu’s arteritis. Tissue Antigens. (1993) 42:87–90. doi: 10.1111/j.1399-0039.1993.tb02242.x
94. Yamamoto T, Shirai K, Okamura K, Urata H. Two years efficacy of paclitaxel-coated balloon dilation for in-stent renal artery restenosis due to Takayasu arteritis. Am J Case Rep. (2019) 20:1089–93. doi: 10.12659/AJCR.916105
95. Chhabra L, Zain MA, Siddiqui WJ. Angioplasty. In: StatPearls. Treasure Island (FL): StatPearls (2023).
96. Auffret V, Berland J, Barragan P, Waliszewski M, Bonello L, Delarche N, et al. Treatment of drug-eluting stents in-stent restenosis with paclitaxel-coated balloon angioplasty: insights from the French “real-world” prospective GARO registry. Int J Cardiol. (2016) 203:690–6. doi: 10.1016/j.ijcard.2015.11.031
97. Virga V, Stabile E, Biamino G, Salemme L, Cioppa A, Giugliano G, et al. Drug-eluting balloons for the treatment of the superficial femoral artery in-stent restenosis: 2-year follow-up. JACC Cardiovasc Interv. (2014) 7:411–5. doi: 10.1016/j.jcin.2013.11.020
98. Samady H, Mekonnen G. Drug-eluting balloons: effective and durable treatment for in-stent restenosis. JACC Cardiovasc Interv. (2013) 6:577–9. doi: 10.1016/j.jcin.2013.04.002
99. Alfonso F, Perez-Vizcayno MJ, Cardenas A, Garcia Del Blanco B, Seidelberger B, Iniguez A, et al. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent). J Am Coll Cardiol. (2014) 63:1378–86. doi: 10.1016/j.jacc.2013.12.006
100. Giacoppo D, Alfonso F, Xu B, Claessen B, Adriaenssens T, Jensen C, et al. Drug-coated balloon angioplasty versus drug-eluting stent implantation in patients with coronary stent restenosis. J Am Coll Cardiol. (2020) 75:2664–78. doi: 10.1016/j.jacc.2020.04.006
101. Wang G, Zhao Q, Chen Q, Zhang X, Tian L, Zhang X. Comparison of drug-eluting balloon with repeat drug-eluting stent for recurrent drug-eluting stent in-stent restenosis. Coron Artery Dis. (2019) 30:473–80. doi: 10.1097/MCA.0000000000000784
102. Wolny R, Kowalik I, Januszek R, Bil J, Figatowski T, Milewski M, et al. Long-term outcomes following drug-eluting balloons vs. thin-strut drug-eluting stents for treatment of recurrent restenosis in drug-eluting stents. Kardiol Pol. (2022) 80:765–73. doi: 10.33963/KP.a2022.0106
103. Shoeib O, Burzotta F. Recurrent restenosis in drug-eluting stents: still looking for the best treatment? Kardiol Pol. (2022) 80:738–40. doi: 10.33963/KP.a2022.0146
104. Tzafriri AR, Vukmirovic N, Kolachalama VB, Astafieva I, Edelman ER. Lesion complexity determines arterial drug distribution after local drug delivery. J Control Release. (2010) 142:332–8. doi: 10.1016/j.jconrel.2009.11.007
105. Hwang CW, Levin AD, Jonas M, Li PH, Edelman ER. Thrombosis modulates arterial drug distribution for drug-eluting stents. Circulation. (2005) 111:1619–26. doi: 10.1161/01.CIR.0000160363.30639.37
106. Speck U, Hackel A, Schellenberger E, Kamann S, Lochel M, Clever YP, et al. Drug distribution and basic pharmacology of paclitaxel/resveratrol-coated balloon catheters. Cardiovasc Intervent Radiol. (2018) 41:1599–1610. doi: 10.1007/s00270-018-2018-9
107. Selvarani R, Mohammed S, Richardson A. Effect of rapamycin on aging and age-related diseases-past and future. Geroscience. (2021) 43:1135–58. doi: 10.1007/s11357-020-00274-1
108. Weaver BA. How taxol/paclitaxel kills cancer cells. Mol Biol Cell. (2014) 25:2677–81. doi: 10.1091/mbc.E14-04-0916
109. Liebmann JE, Cook JA, Lipschultz C, Teague D, Fisher J, Mitchell JB. Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines. Br J Cancer. (1993) 68:1104–9. doi: 10.1038/bjc.1993.488
110. Wessely R, Kastrati A, Mehilli J, Dibra A, Pache J, Schomig A. Randomized trial of rapamycin- and paclitaxel-eluting stents with identical biodegradable polymeric coating and design. Eur Heart J. (2007) 28:2720–5. doi: 10.1093/eurheartj/ehm425
111. Alfonso F, Perez-Vizcayno MJ, Cardenas A, Garcia del Blanco B, Garcia-Touchard A, Lopez-Minguez JR, et al. A prospective randomized trial of drug-eluting balloons versus everolimus-eluting stents in patients with in-stent restenosis of drug-eluting stents: the RIBS IV randomized clinical trial. J Am Coll Cardiol. (2015) 66:23–33. doi: 10.1016/j.jacc.2015.04.063
112. Granada JF, Stenoien M, Buszman PP, Tellez A, Langanki D, Kaluza GL, et al. Mechanisms of tissue uptake and retention of paclitaxel-coated balloons: impact on neointimal proliferation and healing. Open Heart. (2014) 1:e 000117. doi: 10.1136/openhrt-2014-000117
113. Werk M, Albrecht T, Meyer DR, Ahmed MN, Behne A, Dietz U, et al. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv. (2012) 5:831–40. doi: 10.1161/CIRCINTERVENTIONS.112.971630
114. Stolzenburg N, Breinl J, Bienek S, Jaguszewski M, Lochel M, Taupitz M, et al. Paclitaxel-Coated balloons: investigation of drug transfer in healthy and atherosclerotic arteries—first experimental results in rabbits at low inflation pressure. Cardiovasc Drugs Ther. (2016) 30:263–70. doi: 10.1007/s10557-016-6658-1
115. Holmes DR, Vlietstra RE, Smith HC, Vetrovec GW, Kent KM, Cowley MJ, et al. Restenosis after percutaneous transluminal coronary angioplasty (PTCA): a report from the PTCA registry of the National Heart, Lung, and Blood Institute. Am J Cardiol. (1984) 53:77C–81C. doi: 10.1016/0002-9149(84)90752-5
116. Kolachalama VB, Pacetti SD, Franses JW, Stankus JJ, Zhao HQ, Shazly T, et al. Mechanisms of tissue uptake and retention in zotarolimus-coated balloon therapy. Circulation. (2013) 127:2047–55. doi: 10.1161/CIRCULATIONAHA.113.002051
117. Ali RM, Abdul Kader M, Wan Ahmad WA, Ong TK, Liew HB, Omar AF, et al. Treatment of coronary drug-eluting stent restenosis by a sirolimus- or paclitaxel-coated balloon. JACC Cardiovasc Interv. (2019) 12:558–66. doi: 10.1016/j.jcin.2018.11.040
118. Kelsch B, Scheller B, Biedermann M, Clever YP, Schaffner S, Mahnkopf D, et al. Dose response to paclitaxel-coated balloon catheters in the porcine coronary overstretch and stent implantation model. Invest Radiol. (2011) 46:255–63. doi: 10.1097/RLI.0b013e31820577df
119. Gongora CA, Shibuya M, Wessler JD, McGregor J, Tellez A, Cheng Y, et al. Impact of paclitaxel dose on tissue pharmacokinetics and vascular healing: a comparative drug-coated balloon study in the familial hypercholesterolemic swine model of superficial femoral in-stent restenosis. JACC Cardiovasc Interv. (2015) 8:1115–23. doi: 10.1016/j.jcin.2015.03.020
120. Plass CA, Sabdyusheva-Litschauer I, Bernhart A, Samaha E, Petnehazy O, Szentirmai E, et al. Time course of endothelium-dependent and -independent coronary vasomotor response to coronary balloons and stents. Comparison of plain and drug-eluting balloons and stents. JACC Cardiovasc Interv. (2012) 5:741–51. doi: 10.1016/j.jcin.2012.03.021
121. Nakamura T, Brott BC, Brants I, Panchal D, Li J, Chen JP, et al. Vasomotor function after paclitaxel-coated balloon post-dilation in porcine coronary stent model. JACC Cardiovasc Interv. (2011) 4:247–55. doi: 10.1016/j.jcin.2010.08.028
122. Schneider PA, Giasolli R, Ebner A, Virmani R, Granada JF. Early experimental and clinical experience with a focal implant for lower extremity post-angioplasty dissection. JACC Cardiovasc Interv. (2015) 8:347–54. doi: 10.1016/j.jcin.2014.07.032
123. Sharma S, Raut N, Potdar A. Spontaneous coronary artery dissection: case series and review of literature. Indian Heart J. (2016) 68:480–5. doi: 10.1016/j.ihj.2015.11.039
124. Tepe G, Zeller T, Schnorr B, Claussen CD, Beschorner U, Brechtel K, et al. High-grade, non-flow-limiting dissections do not negatively impact long-term outcome after paclitaxel-coated balloon angioplasty: an additional analysis from the THUNDER study. J Endovasc Ther. (2013) 20:792–800. doi: 10.1583/13-4392R.1
125. Wurdinger M, Cammann VL, Ghadri JR, Templin C. Spontaneous coronary artery dissection: a rare event? Heart Fail Clin. (2022) 18:189–99. doi: 10.1016/j.hfc.2021.07.015
126. Fanelli F, Cannavale A, Gazzetti M, D’Adamo A. Commentary: how do we deal with dissection after angioplasty? J Endovasc Ther. (2013) 20:801–4. doi: 10.1583/13-4392C.1
127. Voute MT, Stathis A, Schneider PA, Thomas SD, Brodmann M, Armstrong EJ, et al. Delphi consensus study toward a comprehensive classification system for angioplasty-induced femoropopliteal dissection: the DISFORM study. JACC Cardiovasc Interv. (2021) 14:2391–401. doi: 10.1016/j.jcin.2021.07.056
128. Gray WA, Cardenas JA, Brodmann M, Werner M, Bernardo NI, George JC, et al. Treating post-angioplasty dissection in the femoropopliteal arteries using the tack endovascular system: 12-month results from the TOBA II study. JACC Cardiovasc Interv. (2019) 12:2375–84. doi: 10.1016/j.jcin.2019.08.005
129. Kobayashi N, Hirano K, Yamawaki M, Araki M, Sakai T, Sakamoto Y, et al. Simple classification and clinical outcomes of angiographic dissection after balloon angioplasty for femoropopliteal disease. J Vasc Surg. (2018) 67:1151–58. doi: 10.1016/j.jvs.2017.08.092
130. Kastrati A, Schomig A, Dietz R, Neumann FJ, Richardt G. Time course of restenosis during the first year after emergency coronary stenting. Circulation. (1993) 87:1498–505. doi: 10.1161/01.cir.87.5.1498
131. Gao L, Wang YB, Jing J, Zhang M, Chen YD. Drug-eluting balloons versus new generation drug-eluting stents for the management of in-stent restenosis: an updated meta-analysis of randomized studies. J Geriatr Cardiol. (2019) 16:448–57. doi: 10.11909/j.issn.1671-5411.2019.06.002
132. Ngam PI, Ong CC, Chai P, Wong SS, Liang CR, Teo LLS. Computed tomography coronary angiography—past, present and future. Singapore Med J. (2020) 61:109–15. doi: 10.11622/smedj.2020028
133. Hui L, Shin ES, Jun EJ, Bhak Y, Garg S, Kim TH, et al. Impact of dissection after drug-coated balloon treatment of de novo coronary lesions: angiographic and clinical outcomes. Yonsei Med J. (2020) 61:1004–12. doi: 10.3349/ymj.2020.61.12.1004
134. Tahara S, Chamie D, Baibars M, Alraies C, Costa M. Optical coherence tomography endpoints in stent clinical investigations: strut coverage. Int J Cardiovasc Imaging. (2011) 27:271–87. doi: 10.1007/s10554-011-9796-3
135. Tanigawa J, Barlis P, Di Mario C. Intravascular optical coherence tomography: optimisation of image acquisition and quantitative assessment of stent strut apposition. EuroIntervention. (2007) 3:128–36.19737696
Keywords: drug eluting balloon, arterial circulatory system diseases, coronary artery diseases, instent restenosis, paclitaxel
Citation: Lu K, Ye X, Chen Y, Wang P, Gong M, Xuan B, Tang Z, Li M, Hou J, Peng K and Pei H (2024) Research progress of drug eluting balloon in arterial circulatory system. Front. Cardiovasc. Med. 11:1287852. doi: 10.3389/fcvm.2024.1287852
Received: 2 September 2023; Accepted: 4 March 2024;
Published: 20 March 2024.
Edited by:
Alfonso Ielasi, IRCCS Ospedale Galeazzi Sant’Ambrogio, ItalyReviewed by:
Jumpei Saito, National Center for Child Health and Development (NCCHD), JapanMonika Colombo, Aarhus University, Denmark
© 2024 Lu, Ye, Chen, Wang, Gong, Xuan, Tang, Li, Hou, Peng and Pei. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Haifeng Pei peihaifeng@swjtu.edu.cn Ke Peng drpeng209@126.com
†These authors have contributed equally to this work
Abbreviations DEB, drug eluting balloon; BMS, bare metal support; DES, drug eluting stent; EES, everolimus eluting stent; ISR, in-stent restenosis; TRAS, renal artery stenosis after kidney transplantation; FMD, fibromuscular dysplasia.